BioCentury
ARTICLE | Clinical News

Phase II results for Palatin's LeuTech

June 25, 2001 7:00 AM UTC

PTN said that interim results from 19 patients in a Phase II trial showed that its LeuTech radiolabeled monoclonal antibody that binds activated white blood cells is safe and provides a diagnostic ima...